Gamma-aminobutyric acid type A receptor alpha-6 beta-3 gamma-2 (GABAA receptor α6β3γ2)

The GABAA receptor α6β3γ2 is a specific heteropentameric subtype of the ionotropic gamma-aminobutyric acid (GABA) receptor, which is the primary inhibitory neurotransmitter receptor in the central nervous system [1]. This receptor is uniquely characterized by the presence of the α6 subunit, which is almost exclusively expressed in the granule cells of the cerebellum [2]. A defining pharmacological feature of this subtype is its insensitivity to classical benzodiazepines, such as diazepam, due to a specific arginine residue in the α6 subunit that replaces the conserved histidine found in diazepam-sensitive subunits [15]. Functionally, the α6β3γ2 isoform is primarily localized at synapses where it mediates phasic inhibition, playing a critical role in the precise timing of cerebellar motor and cognitive outputs [2, 7]. Dysregulation of α6-containing receptors is implicated in various conditions, including essential tremor, tinnitus, migraine, and neuropsychiatric disorders such as schizophrenia and anxiety [2, 7]. Current therapeutic research focuses on developing subtype-selective positive allosteric modulators (PAMs) that target the α+β- interface, offering potential for treating movement disorders and chronic pain with a reduced risk of the sedative side effects associated with broad-spectrum GABAergic drugs [3, 4].

Other names

GABA(A) receptor alpha6beta3gamma2GABRA6-GABRB3-GABRG2 receptorDiazepam-insensitive GABAA receptorα6β3γ2 GABAA receptor

Positive allosteric modulation, Negative allosteric modulation, Ligand-gated chloride channel activation